Dynamics in Post-pandemic Global Radioimmunotherapy Industry: Supply and Demand, Markets and Prices 2021-2027

Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Radioimmunotherapy Market Status and Forecast (2016-2027)
  • 1.3.2 Global Radioimmunotherapy Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Radioimmunotherapy Supply by Company

• 2.1 Global Radioimmunotherapy Sales Value by Company
• 2.2 Radioimmunotherapy Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Radioimmunotherapy Market Status by Category

• 3.1 Radioimmunotherapy Category Introduction
  • 3.1.1 Non Hodgkin Lymphoma (NHL)
  • 3.1.2 Follicular Lymphoma
  • 3.1.3 Solid Tumors
  • 3.1.4 Breast Cancer
  • 3.1.5 Ovarian Cancer
  • 3.1.6 Osteosarcoma
  • 3.1.7 Neuroblastoma
  • 3.1.8 Prostate Cancer
• 3.2 Global Radioimmunotherapy Market by Category
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Radioimmunotherapy Market Status by End User/Segment

• 4.1 Radioimmunotherapy Segment by End User/Segment
  • 4.1.1 Tumor Antigens
  • 4.1.2 Radionuclides
  • 4.1.3 Antibodies
• 4.2 Global Radioimmunotherapy Market by End User/Segment
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Radioimmunotherapy Market Status by Region

• 5.1 Global Radioimmunotherapy Market by Region
• 5.2 North America Radioimmunotherapy Market Status
• 5.3 Europe Radioimmunotherapy Market Status
• 5.4 Asia Pacific Radioimmunotherapy Market Status
• 5.5 Central & South America Radioimmunotherapy Market Status
• 5.6 Middle East & Africa Radioimmunotherapy Market Status

6 North America Radioimmunotherapy Market Status

• 6.1 North America Radioimmunotherapy Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Radioimmunotherapy Market Status

• 7.1 Europe Radioimmunotherapy Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Radioimmunotherapy Market Status

• 8.1 Asia Pacific Radioimmunotherapy Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Radioimmunotherapy Market Status

• 9.1 Central & South America Radioimmunotherapy Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Radioimmunotherapy Market Status

• 10.1 Middle East & Africa Radioimmunotherapy Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Radioimmunotherapy Market Forecast by Category and by End User/Segment

• 12.1 Global Radioimmunotherapy Sales Value Forecast (2022-2027)
• 12.2 Global Radioimmunotherapy Forecast by Category
• 12.3 Global Radioimmunotherapy Forecast by End User/Segment

13 Global Radioimmunotherapy Market Forecast by Region/Country

• 13.1 Global Radioimmunotherapy Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Telix Pharmaceuticals
  • 14.1.1 Company Information
  • 14.1.2 Radioimmunotherapy Product Introduction
  • 14.1.3 Telix Pharmaceuticals Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Stella Pharma
  • 14.2.1 Company Information
  • 14.2.2 Radioimmunotherapy Product Introduction
  • 14.2.3 Stella Pharma Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 RadioMedix
  • 14.3.1 Company Information
  • 14.3.2 Radioimmunotherapy Product Introduction
  • 14.3.3 RadioMedix Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Philogen
  • 14.4.1 Company Information
  • 14.4.2 Radioimmunotherapy Product Introduction
  • 14.4.3 Philogen Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 PDL Biopharma
  • 14.5.1 Company Information
  • 14.5.2 Radioimmunotherapy Product Introduction
  • 14.5.3 PDL Biopharma Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Nordic Nanovector
  • 14.6.1 Company Information
  • 14.6.2 Radioimmunotherapy Product Introduction
  • 14.6.3 Nordic Nanovector Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Molecular Insight Pharmaceuticals
  • 14.7.1 Company Information
  • 14.7.2 Radioimmunotherapy Product Introduction
  • 14.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Immunomedics
  • 14.8.1 Company Information
  • 14.8.2 Radioimmunotherapy Product Introduction
  • 14.8.3 Immunomedics Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Endocyte
  • 14.9.1 Company Information
  • 14.9.2 Radioimmunotherapy Product Introduction
  • 14.9.3 Endocyte Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Curasight
  • 14.10.1 Company Information
  • 14.10.2 Radioimmunotherapy Product Introduction
  • 14.10.3 Curasight Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Clarity Pharmaceuticals
• 14.12 BioSynthema
• 14.13 Bayer Healthcare Pharmaceuticals

15 Conclusion

16 Methodology